Abstract: The display device comprises a first base portion including display and non-display areas and a pad area, and a printed circuit film attached to the pad area of the first base portion, wherein pad electrodes on the first base portion and a first panel alignment mark on one side of the plurality of pad electrodes are disposed in the pad area, a first protective layer is on the pad electrodes, and a first open portion that exposes a portion of an upper surface of each pad electrode is defined in the protective layer, the printed circuit film includes a third base portion and lead electrodes on a lower surface of the third base portion and connected to the pad electrodes, and the first panel alignment mark includes a first panel alignment metal portion and a second open portion and surrounded by the first panel alignment metal portion on a plane.

Abstract: Disclosed is an oligonucleotide-modified nucleic acid containing at least one 1-?-D-arabinofuranosylcytosine as a modified nucleic acid having therapeutic efficacies and guanosine. More particularly, a novel oligonucleotide-modified nucleic acid containing at least one modified nucleic acid (N) having therapeutic efficacies and being rich in guanosine (G) is synthesized and the fact that the novel oligonucleotide-modified nucleic acid has excellent apoptotic activities on blood cancer cells and drug-resistant blood cancer cells is identified. Based on this, provided is a composition for preventing, ameliorating or treating blood cancer, containing the novel oligonucleotide-modified nucleic acid, and the novel oligonucleotide-modified nucleic acid or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: A method for manufacturing a display device includes checking a particle positioned between a display panel and a connecting member, irradiating a laser to an upper surface of the connecting member overlapping at least a part of the particle, removing the connecting member overlapping a region to which the laser is irradiated, removing the particle overlapping a region to which the laser is irradiated, and disposing a desiccant in a hole formed by removing the connecting member and the particle.

Abstract: Disclosed is an oral pharmaceutical composition for preventing or treating dry eye syndrome, which comprises rebamipide or a prodrug thereof, or a pharmaceutically acceptable salt thereof, as an active ingredient. The compounds can treat dry eye syndrome via oral route, and can be thus employed safely and conveniently compared to conventional eye drops.

Abstract: Disclosed is an oligonucleotide-modified nucleic acid containing at least one 1-?-D-arabinofuranosylcytosine as a modified nucleic acid having therapeutic efficacies and guanosine. More particularly, a novel oligonucleotide-modified nucleic acid containing at least one modified nucleic acid (N) having therapeutic efficacies and being rich in guanosine (G) is synthesized and the fact that the novel oligonucleotide-modified nucleic acid has excellent apoptotic activities on blood cancer cells and drug-resistant blood cancer cells is identified. Based on this, provided is a composition for preventing, ameliorating or treating blood cancer, containing the novel oligonucleotide-modified nucleic acid, and the novel oligonucleotide-modified nucleic acid or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: A bonding apparatus includes: an anisotropic conductive film (“ACF”) attachment unit which attaches a first ACF and a second ACF onto a display panel assembly; a compression unit which compresses a first chip-on-film (“COF”) on the first ACF and compresses a second COF on the second ACF; and a buffer unit which rotates the display panel assembly, on which the first ACF and the second COF are compressed, on a plane.

Abstract: A method for manufacturing a display device includes checking a particle positioned between a display panel and a connecting member, irradiating a laser to an upper surface of the connecting member overlapping at least a part of the particle, removing the connecting member overlapping a region to which the laser is irradiated, removing the particle overlapping a region to which the laser is irradiated, and disposing a desiccant in a hole formed by removing the connecting member and the particle.

Abstract: A display device includes a display area; a pad area including a first pad for supplying a data signal to the display area, second pads for transmitting a DC signal, and a dummy pad, wherein each of the first pad, the second pads, and the dummy pad has a surface as a top face thereof, wherein each of the surface of the first pad, the surface of the second pads, and the surface of the dummy pad has a corresponding vertical level in a thickness direction of the display device, wherein the vertical level of the surface of each of the second pads is higher than the vertical level of the surface of the first pad, wherein the vertical level of the surface of the dummy pad is lower than or equal to the vertical level of the surface of the first pad.

Abstract: Disclosed are a novel rebamipide prodrug, a method for preparing the same, and use thereof. Also, a pharmaceutical composition comprising the novel rebamipide prodrug as an active ingredient is provided. The rebamipide prodrug is increased 25-fold in absorption rate compared to rebamipide itself, and can be applied to the prophylaxis or therapy of gastric ulcer, acute gastritis, chronic gastritis, xerophthalmia, cancer, osteoarthritis, rheumatoid arthritis, or obesity.

Abstract: A method for manufacturing a display device includes checking a particle positioned between a display panel and a connecting member, irradiating a laser to an upper surface of the connecting member overlapping at least a part of the particle, removing the connecting member overlapping a region to which the laser is irradiated, removing the particle overlapping a region to which the laser is irradiated, and disposing a desiccant in a hole formed by removing the connecting member and the particle.

Abstract: The display device comprises a first base portion including display and non-display areas and a pad area, and a printed circuit film attached to the pad area of the first base portion, wherein pad electrodes on the first base portion and a first panel alignment mark on one side of the plurality of pad electrodes are disposed in the pad area, a first protective layer is on the pad electrodes, and a first open portion that exposes a portion of an upper surface of each pad electrode is defined in the protective layer, the printed circuit film includes a third base portion and lead electrodes on a lower surface of the third base portion and connected to the pad electrodes, and the first panel alignment mark includes a first panel alignment metal portion and a second open portion and surrounded by the first panel alignment metal portion on a plane.

Abstract: A method for manufacturing a display device includes checking a particle positioned between a display panel and a connecting member, irradiating a laser to an upper surface of the connecting member overlapping at least a part of the particle, removing the connecting member overlapping a region to which the laser is irradiated, removing the particle overlapping a region to which the laser is irradiated, and disposing a desiccant in a hole formed by removing the connecting member and the particle.

Abstract: The present invention provides a novel pyridine derivative, a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient. The pyridine derivative according to the present invention inhibits Raf kinase (B-Raf, Raf-1, or B-RafV600E) and a vascular endothelial growth factor receptor (VEGFR2) involved in angiogenesis, and thus, can be favorably used for the prevention or treatment of melanoma, colorectal cancer, prostate cancer, thyroid cancer, lung cancer, pancreatic cancer, ovarian cancer, or the like, which is induced by RAS mutation.

Abstract: A bonding apparatus includes: an anisotropic conductive film (“ACF”) attachment unit which attaches a first ACF and a second ACF onto a display panel assembly; a compression unit which compresses a first chip-on-film (“COF”) on the first ACF and compresses a second COF on the second ACF; and a buffer unit which rotates the display panel assembly, on which the first ACF and the second COF are compressed, on a plane.

Abstract: The present invention relates to an inclusion compound of fumagillol derivative or its salt with hydroxypropyl-?-cyclodextrin or sulfobutylether-7-?-cyclodextrin, and pharmaceutical compositions comprising the same. The inclusion compound according to the present invention has superior water solubility and stability while exhibiting low toxicity, rendering it valuable as an anticancer agent or inhibitor of tumor metastasis.

Abstract: The present invention provides a novel pyridine derivative, a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient. The pyridine derivative according to the present invention inhibits Raf kinase (B-Raf, Raf-1, or B-RafV600E) and a vascular endothelial growth factor receptor (VEGFR2) involved in angiogenesis, and thus, can be favorably used for the prevention or treatment of melanoma, colorectal cancer, prostate cancer, thyroid cancer, lung cancer, pancreatic cancer, ovarian cancer, or the like, which is induced by RAS mutation.

Abstract: The present invention relates to an inclusion compound of fumagillol derivative or its salt with hydroxypropyl-?-cyclodextrin or sulfobutylether-7-?-cyclodextrin, and pharmaceutical compositions comprising the same. The inclusion compound according to the present invention has superior water solubility and stability while exhibiting low toxicity, rendering it valuable as an anticancer agent or inhibitor of tumor metastasis.

Abstract: The present invention relates to an inclusion compound of fumagillol derivative or its salt with hydroxypropyl-?-cyclodextrin or sulfobutylether-7-?-cyclodextrin, and pharmaceutical compositions comprising the same. The inclusion compound according to the present invention has superior water solubility and stability while exhibiting low toxicity, rendering it valuable as an anticancer agent or inhibitor of tumor metastasis.

Abstract: Disclosed is an oral pharmaceutical composition for preventing or treating dry eye syndrome, which comprises rebamipide or a prodrug thereof, or a pharmaceutically acceptable salt thereof, as an active ingredient. The compounds can treat dry eye syndrome via oral route, and can be thus employed safely and conveniently compared to conventional eye drops.

Abstract: The present invention relates to an inclusion compound of fumagillol derivative or its salt with hydroxypropyl-?-cyclodextrin or sulfobutylether-7-?-cyclodextrin, and pharmaceutical compositions comprising the same. The inclusion compound according to the present invention has superior water solubility and stability while exhibiting low toxicity, rendering it valuable as an anticancer agent or inhibitor of tumor metastasis.